Rite Aid Addresses Cyberattack: 2.2 Million Customers’ Data Breached
Drug Topics
JULY 17, 2024
The retail pharmacy chain issued an alert to its customers that purchasing data from 2017 to 2018 may have been breached by a third party.
2017 Related Topics 
FDA: Fasenra Approved As Add-On Maintenance Therapy for Severe Pediatric Asthma
Drug Topics
APRIL 12, 2024
Fasenra was initially approved in 2017 as an add on maintenance therapy in patients aged 12 years and older.
FDA 
387
387 FDA 387
387 Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
STAT+: Life sciences deals on track to hit lowest point since 2017
STAT
OCTOBER 11, 2023
If dealmaking remains consistent for the rest of the year, it would put this year on par with the number of deals made in 2017. For comparison, there were roughly 2,122 financing deals made last year. Continue to STAT+ to read the full story…
140 
Merck settles with insurance companies over $1.4B claim tied to 2017 cyberattack: report
Fierce Pharma
JANUARY 4, 2024
billion claim after it was victimized by a crippling cyberattack in 2017. billion claim after it was victimized by a crippling cyberattack in 2017, Bloomberg Law reports. Merck has reportedly settled with insurance companies that contested the pharma giant’s $1.4
Insurance 108
108 Insurance 108
108 
Preserving Patient Access to Compounded Medications Act of 2017
Pharmacy Times
SEPTEMBER 14, 2023
The act would have permitted health care facilities to stock up on compounded medications without forcing the supplying 503A pharmacies to register as outsourcing facilities.
Compounding 139
139 Compounding 139
139 
Adderall Shortage Led to More Alternative Stimulant Prescriptions for US Children
Drug Topics
JANUARY 27, 2025
Researchers analyzed overall prescription stimulant dispensing trends among US children from 2017 to 2023.
247 
STAT+: FTC slams PBMs for boosting specialty drug prices at the expense of the U.S. health care system
STAT
JANUARY 14, 2025
billion in revenue by dispensing medicines to treat cancer, HIV, heart disease and other serious illnesses at prices that exceeded their estimated acquisition costs between 2017 and 2022. Specifically, the companies were able to generate more than $7.3 Continue to STAT+ to read the full story…
Insurance 144
144 Insurance 144
144 
STAT+: Two of FDA’s top cancer regulators to depart, heightening worries about drug reviews
STAT
MARCH 27, 2025
The FDA’s Oncology Center of Evidence was created in 2017 by Congress as a way to speed the development of cancer treatments. Theoret, who joined as a medical reviewer in 2009, have told colleagues of plans to leave the FDA, multiple sources familiar with the matter told STAT.
FDA 142
142 FDA 142
142 
Dupilumab Safe, Effective for Atopic Dermatitis in Real-Life Settings
Drug Topics
MARCH 4, 2024
In 2017, dupilumab became the first treatment approved in Canada for moderate to severe AD, as multiple clinical trials demonstrated its effectiveness and safety.
247 
STAT+: To mitigate drug shortages, a new study suggests looking at Canada
STAT
OCTOBER 31, 2024
Between 2017 and 2021, regulators in the U.S. Of 104 reports of supply chain issues with dozens of drugs, meaningful shortages were 40% less likely to occur in Canada than in the U.S., a new study found, and the difference was largely attributed to the approach taken by the Canadian government to the problem.
FDA 138
138 FDA 138
138 
STAT+: Gilead will pay $202 million to settle charges of paying kickbacks to docs for boosting HIV drug sales
STAT
APRIL 29, 2025
From 2011 through 2017, Gilead held more than 17,300 speaker programs of which 9,500 were dinners to promote sales of HIV drugs that were supposed to be educational. The dinners were at expensive restaurants that federal authorities maintained were “wholly inappropriate” venues for such gatherings.
117 
STAT+: DOJ probes device maker whose test resulted in lucrative diagnoses for UnitedHealth and other insurers
STAT
MARCH 3, 2025
The company indicated that the investigation began in 2017 and picked up in intensity in late 2024 and early 2025. The SEC filing states that on Feb. Continue to STAT+ to read the full story…
Insurance 142
142 Insurance 142
142 
PTC wins FDA approval for first brain-delivered gene therapy Kebilidi
Fierce Pharma
NOVEMBER 14, 2024
The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy has already been approved to treat AADC deficiency in Europe and the U.K., among other countries, where it's branded as Upstaza.
FDA 143
143 FDA 143
143 
STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail
STAT
OCTOBER 12, 2023
Good morning, everyone, and welcome to another busy day. We are scrambling, in fact, to update our to-do list, schedule online calls, and sort out deadlines. To cope, we are quaffing several cups of stimulation, of course. Our choice today is maple bourbon. Meanwhile, here is the latest selection of interesting items for you to peruse.
102 
STAT+: Belgian anti-trust authorities probe Roche for allegedly delaying biosimilars of two cancer meds
STAT
MARCH 17, 2025
In a brief statement , the Belgian Competition Authority alleged that Roche offered financial incentives to hospitals between 2017 and 2020 to deter them from considering competitive bids from other pharmaceutical companies that could supply similar medicines.
STAT+: Device maker that helped UnitedHealth collect billions offers to settle fraud claims with DOJ
STAT
APRIL 16, 2025
The DOJ began looking into the company in 2017, according to Semler, but re-upped its investigation in late 2024 and early 2025. The deal would cap an investigation Semler first disclosed in February into whether federal health programs paid out improper claims based on the use of QuantaFlo, which would violate the False Claims Act.
Insurance 123
123 Insurance 123
123 
Updated USPSTF Guidelines Show Benefits of Screening for Obstructive Sleep Apnea Do Not Outweigh Harms
Pharmacy Times
DECEMBER 9, 2022
The decision is updated from a 2017 recommendation to screen people for obstructive sleep apnea, which can lead to daytime sleepiness and other adverse outcomes.
139 
With FDA nod for Onivyde combo, Ipsen ends 10-year drought in newly diagnosed pancreatic cancer
Fierce Pharma
FEBRUARY 13, 2024
It’s the approval Ipsen has been waiting for since buying up Onivyde in 2017. It’s the approval Ipsen has been waiting for since buying up Onivyde in 2017. The FDA has approved Onivyde as part of a combination dubbed Nalirifox to treat patients with newly diagnosed metastatic pancreatic cancer.
FDA 122
122 FDA 122
122 
Risks Facing Pharmacists, and Their Associated Costs, Are Increasing
Pharmacy Times
DECEMBER 21, 2023
The cost of defending license matters and malpractice claim costs have increased over a 5-year period (2017-2022).
132 
Vision loss and high cholesterol identified as risk factors for dementia
STAT
JULY 31, 2024
These new additions join 12 other risk factors outlined by the commission, affiliated with University College London, in previous reports on dementia prevention, intervention, and care in 2017 and 2020.
145 
FDA Approves Cerliponase Alfa for Expanded Indication of CLN2 Disease
Pharmacy Times
JULY 24, 2024
In April 2017, the drug was approved to treat the slow loss of the ability to walk for symptomatic patients aged 3 and older who had Batten disease.
FDA 122
122 FDA 122
122 
Public Health Matters - Loving the Pharmacy Profession, Helping Patients
Pharmacy Times
DECEMBER 22, 2022
Alex Barker founded The Happy PharmD to provide career coaching and career development classes, and since 2017, the company has helped over 1,500 pharmacists.
132 
STAT+: Pharmalittle: We’re reading about FTC criticizing PBMs, a NIH policy on access to medicines, and more
STAT
JANUARY 15, 2025
billion in revenue by dispensing medicines to treat cancer, HIV, heart disease, and other serious illnesses at prices that exceeded their estimated acquisition costs between 2017 and 2022. Specifically, the companies were able to generate more than $7.3 A federal watchdog weighed in on the U.S.
Insurance 114
114 
The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs
The FDA Law Blog
APRIL 8, 2025
The DCAP was an initiative launched in 2017 to remove barriers to generic drug development, approval, and market entry (see our previous post here ). About one third of these PSGs are for complex products and many reflect what OGD and DPD learned about the science of equivalence from GDUFA-funded regulatory science research.
FDA 144
144 
Opinion: The U.S. should follow California’s lead on banning toxic chemicals in IV bags and tubes
STAT
SEPTEMBER 18, 2024
In 2017, at the age of 42, Susan Whitehead was diagnosed with an early form of breast cancer after discovering a lump in her breast. She embarked on a challenging path of treatment, including a recurrence with stage 2 cancer four years later. Susan underwent two lumpectomies, a mastectomy, radiation, and chemotherapy.
Chemotherapy 129
129 Chemotherapy 129
129 
Roche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus
Fierce Pharma
SEPTEMBER 13, 2024
When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | The day after Roche gained an FDA approval for its subcutaneous version of cancer drug Tecentriq, the company also scored with a U.S. nod for its under-the-skin formulation of mega-blockbuster multiple sclerosis drug Ocrevus.
FDA 120
120 FDA 120
120 
Mapping the crisis: How data can help fix America’s growing pharmacy deserts
pharmaphorum
JUNE 12, 2025
Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)
Federal officials and physician groups express outrage over revelations of recent coercive sterilizations
STAT
JUNE 6, 2024
Federal officials, medical organizations, and reproductive health advocacy groups have expressed outrage in response to STAT’s recent investigation revealing that women with sickle cell disease have felt pressured into sterilizations as recently as 2017 and 2022.
144 
Bill Nye, Science Guy, speaks out on ataxia
STAT
OCTOBER 10, 2024
Nye has previously spoken about the genetic disease, which makes it difficult for people with the condition to control their muscles and often leads to problems with walking and speech, in a documentary released in 2017. He said then that he didn’t have children because of concerns he would pass on the disease to them.
138 
FDA Approves Benralizumab to Treat Pediatric Patients Aged 6 to 11 Years With Severe Asthma
Pharmacy Times
APRIL 11, 2024
Benralizumab was previously approved by the FDA in 2017 as an add-on maintenance therapy for patients 12 years and older.
FDA 111
111 FDA 111
111 
Idorsia's Tryvio crosses FDA finish line, offering new mechanism to treat hypertension
Fierce Pharma
MARCH 20, 2024
After Johnson & Johnson last year changed its mind on its 2017 purchase of ap | Idorsia's Tryvio is the first oral anti-hypertensive therapy that uses a new therapeutic mechanism in nearly 40 years, suggesting the dawn of "a new era of endothelin research," the company said.
FDA 120
120 FDA 120
120 
Daiichi Sankyo scores $182M from Novartis settlement in long-running patent case
Fierce Pharma
DECEMBER 6, 2023
In 2017, Daiichi's former subsidiary Plexxikon alleged that Novartis stepped on its Zelboraf patents with its GSK-acquired medicine Tafinlar. After years of back and forth with Daiichi Sankyo over cancer drug patent claims, Novartis has thrown in the towel with a $182 million settlement. |
121 
Samsung Biologics upgrades another production pact, this time with Baxter for $223M
Fierce Pharma
JUNE 20, 2024
The revised deal, first established back in July of 2017, will now see Baxter pay Samsung upwards of $223 million for its manufacturing services through end of 2034. On a revised dealmaking spree this year, Korea’s Samsung Biologics is re-tooling its long-running drug manufacturing pact with Baxter Healthcare. |
112 
Support for continued progress is critical for pediatric drug development
PhRMA
MAY 8, 2023
 After ibrutinib was initially approved in 2017 for adult patients with cGVHD who have tried and failed on at least one previous medicine, the U.S. For example, ibrutinib was awarded BPCA pediatric exclusivity based on the sponsor’s research into use of the drug in pediatric chronic graft-versus-host disease (cGVHD) patients. After
FDA 262
262 FDA 262
262 
STAT+: How sickle cell became the first disease treated by CRISPR
STAT
DECEMBER 4, 2023
“We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9 , which promised to cure numerous genetic diseases.
Documentation 145
145 Documentation 145
145 
STAT+: As AI proliferates, biopharma companies seek to harness it in clinical trials
STAT
APRIL 3, 2024
That was until 2017, when he founded a startup called Nucleai. For around 20 years, Avi Veidman spent his days in the Israeli intelligence community, analyzing satellite images. Now, he’s scouring biopsy samples for cancer cells. Nucleai’s technology is not searching out signs of danger.
139 
Study points to weaknesses in FDA accelerated approval path
pharmaphorum
APRIL 8, 2024
Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years
FDA 110
110 FDA 110
110 
'Most' cancer meds approved under FDA's accelerated pathway couldn't prove survival benefit after 5 years: study
Fierce Pharma
APRIL 8, 2024
Many cancer meds approved under the FDA's accelerated approval pathway from 2013 to 2017 didn't improve overall survival after more than five years of follow-up research, the study found. One hallmark of the FDA's accelerated approval pathway is the requirement that medicines prove their benefits in confirmatory trials.
FDA 117
117 FDA 117
117 
Avive pockets $57M for portable defibrillator to speed up cardiac arrest response
Fierce Healthcare
APRIL 19, 2024
The company, which launched in 2017, has contracts with four cities for its network of AEDs to improve survival rates of sudden cardiac arrest. Portable defibrillator company Avive Solutions raised $56.5 million in growth equity financing to build out its staff and commercial developments. |
116 
STAT+: Addiction treatment center founder indicted in sprawling fraud scheme
STAT
MAY 24, 2023
Over the last few years, Daniel Cleggett Jr. appeared to be living a charmed life.
145 
Sanofi stands behind 'accuracy of our accounts' amid reports of French manipulation probe
Fierce Pharma
NOVEMBER 7, 2023
Since launching the Regeneron-partnered antibody Dupixent in 2017, Sanofi has relied on the star medicine for sales growth.
STAT+: NIH postdocs will get a raise next year — but not as much as they hoped
STAT
APRIL 23, 2024
But the agency noted in a press release that it’s the largest year-over-year update for NIH-funded postdocs since 2017. The 8% pay bump is far short of the increase to $70,000 that was recommended by an NIH working group late last year.
141 
Merck, insurers advance fight over cyberattack-related coverage to New Jersey Supreme Court
Fierce Pharma
JULY 27, 2023
scored a legal win in the insurance case tied to the 2017 "NotPetya" cyberattack, the case is in appeals—again. scored a legal win in the insurance case tied to the 2017 "NotPetya" cyberattack, the case is in appeals—again. About a month and a half after Merck & Co. That didn't take long.
Insurance 98
98 Insurance 98
98 
STAT+: AbbVie dramatically outspent its pharma company rivals in 2023 to promote its drugs to doctors
STAT
JULY 5, 2024
The massive sum spent by AbbVie, the maker of the mega blockbuster anti-inflammatory drug Humira, is the most a pharmaceutical company has spent on marketing to doctors since such data became available in 2017.
Let's personalize your content